Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.27

-0.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4479)	8/15/2001 3:40:09 PM
From: Ian@SI	Read Replies (1) of 52153

Peter, Does it make any difference whether the source was from "shorts" or someone / something else? If there's a risk of kidney failure from BPUR's product, what doctor is going to abandon the existing product which doesn't have that safety issue. With the rough time that the FDA is giving HMSL on its product (derived from human blood as opposed to BPUR using a bovine source), I'd be very surprised to see BPUR get any slack whatsoever. FWIW, Ian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next